Cannabinoid Acid Ester Compositions for Decarboxylation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cannabinoid compounds, such as THC, CBN, and their precursors like THCA, CBGA, and CBNA, are unstable and have limited therapeutic applications due to their susceptibility to decarboxylation, necessitating the development of more stable forms for effective therapeutic use.
Innovation Solution
The development of cannabinoid acid ester compounds, including THCA esters, CBGA esters, and CBNA esters, which are more stable and provide a variety of therapeutic applications, including combination therapies with other cannabinoid compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If cannabinoid acid compounds (THCA, CBGA, CBNA) are used directly, then they serve as precursors to natural cannabinoids, but they are unstable and susceptible to decarboxylation
Solution Approach 1:
The patent uses esterification to convert cannabinoid acid compounds into ester derivatives, where the ester group acts as a protective intermediary that prevents decarboxylation. The ester derivative serves as a stable intermediate form that can be administered therapeutically without undergoing unwanted decarboxylation, thus resolving the instability issue of the parent cannabinoid acid compounds
Solution Approach 2:
The patent changes the chemical parameter of the cannabinoid acid compounds by converting them to ester derivatives through esterification. This chemical modification alters the stability parameter, making the compounds resistant to decarboxylation while maintaining their therapeutic properties. The parameter change from acid form to ester form directly addresses the stability-reliability contradiction
2Adaptability or versatility
If traditional cannabinoid compounds are used for therapeutic applications, then they have known biological activities, but they have limited therapeutic applications and require stable forms for effective use
Solution Approach 1:
The patent demonstrates that cannabinoid acid ester derivatives can serve multiple therapeutic functions beyond the traditional cannabinoid compounds. The ester derivatives maintain the biological activity of the parent compounds while adding the new function of stability, enabling broader therapeutic applications including treatments for conditions where stable cannabinoid compounds are needed
Solution Approach 2:
By changing the chemical parameter from acid to ester form, the patent enables the compounds to function effectively in therapeutic applications that require stability. The parameter change allows the same core molecule to be used in diverse therapeutic contexts where stability is critical, thus expanding adaptability while solving the stability limitation
Data Source
AI summary
The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a tetrahydrocannabinolic acid (THCA) ester. In some embodiments, the cannabinoid acid ester compound is a cannabigerolic (CBGA) acid ester. In some embodiments, the cannabinoid acid ester compound is a cannabinolic (CBNA) acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.